Sponsors (16)
The bill increases naloxone availability and training across federal and private worksites—potentially saving lives—while imposing modest costs, leaving some coverage gaps due to nonmandatory guidance and exclusions, and accelerating rulemaking that could compress stakeholder input.
Workers (private and federal), veterans, visitors, and bystanders are more likely to have access to naloxone on-site and to receive training, increasing chances of reversing opioid overdoses.
Employers and federal agencies receive OSHA-backed guidance and standardized requirements that simplify implementation and promote consistent availability of overdose reversal medication across worksites.
The bill encourages voluntary annual training and preparedness without creating new mandatory regulatory burdens for private employers, preserving flexibility for small businesses.
Employers (especially small businesses) and federal agencies will incur costs to buy, store, replenish naloxone and provide training, increasing operating expenses and potentially raising taxpayer-funded costs.
Because guidance for private employers is nonmandatory and the employer definition excludes the U.S. Postal Service, some workplaces (including USPS sites) may remain without naloxone or training, leaving coverage gaps.
A 270‑day accelerated deadline for OSHA rulemaking may limit stakeholder input and detailed implementation planning, risking inconsistent rollout, administrative strain, or legal challenges.
Based on analysis of 3 sections of legislative text.
OSHA must issue employer guidance and must require all federal agencies to stock opioid overdose reversal medication and offer voluntary annual training within 270 days.
Requires the Department of Labor, through OSHA, to produce nonbinding employer guidance within 270 days about acquiring and maintaining opioid overdose reversal medication (e.g., naloxone) and offering voluntary annual employee training. It also directs OSHA to issue binding regulations within 270 days that require every federal agency to acquire and maintain overdose reversal medication and offer voluntary annual training to employees, including the Veterans Health Administration.
Official title: To require the Secretary of Labor to issue guidance and regulations regarding opioid overdose reversal medication and employee training.
Introduced February 10, 2026 by Bonnie Watson Coleman · Last progress February 10, 2026